AMS is pleased to announce that Hiroyuki Okada, Co-Founder and CEO of MIRAISOUZOU (MIRAI), has been appointed as an outside director of AMS, on 16 December 2022.

Okada joined TEPCO in 1996, where he was involved in developing Next Generation Nuclear Reactors in the Nuclear Energy Division. After that, he was transferred to TNP Partners (VC), where he was in charge of hands-on support. With a deep understanding of large enterprises, small businesses, business companies, and finance, he has accumulated much experience in strategic planning and implementation, from business composition to service and sales strategy.

Okada has a B.S. in Materials Science and an M.S. in Nuclear Engineering from the Tokyo Institute of Technology and holds a Chief Nuclear Reactor Engineer license in Japan.

Yuichiro Sugawara, AMS's Founder and CEO, said, "Okada brings new insights into our nuclear medicine business based on his deep understanding of the nuclear industry and equity finance. His experience in TEPCO as a Chief Nuclear Reactor Engineer will be precious for AMS to drive our business beyond the healthcare field."